PTH
EstablishedPTH is central to diagnosing hyperparathyroidism and CKD-related bone disease, with genuinely distinct target ranges for each.
PTH controls calcium levels in the blood and bone. In kidney disease, doctors don't aim for a "normal" PTH level like they would in other situations — instead, they aim for a wider range specifically because pushing it down too far can actually harm bone health in kidney patients.
Parathyroid hormone (PTH) regulates calcium and phosphate balance by acting on bone, kidney, and (indirectly) intestine; it is central to diagnosing both primary hyperparathyroidism and disorders of chronic kidney disease-related bone and mineral metabolism.
Elevated PTH with high calcium suggests primary hyperparathyroidism (usually a parathyroid adenoma); elevated PTH with low or normal calcium in a patient with reduced kidney function suggests secondary hyperparathyroidism from chronic kidney disease-mineral and bone disorder (CKD-MBD).
Measured via second-generation "intact PTH" immunoassay; a genuine assay limitation exists since these assays measure a mix of full-length active PTH and various circulating fragments, contributing to real result variability between different testing platforms.
A genuinely counterintuitive current guideline: KDIGO recommends keeping dialysis-patient PTH within a wide range (roughly 2-9x the assay's upper limit), not "normal," because assay variability and PTH-resistance in uremia mean overly aggressive lowering risks adynamic bone disease — a real case where "normal" isn't the treatment target.
The CKD-MBD target range (2-9x upper normal limit) is intentionally wide, not "normal," reflecting real assay and physiologic complexities.
- PMC. (2019). Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.